每經訊，豫辰(chen)(chen)藥業11月18日發布公(gong)告(gao)稱，2022年(nian)11月24日，路(lu)明通(tong)過認(ren)購公(gong)司(si)定向(xiang)發行股(gu)(gu)(gu)(gu)(gu)份(fen)的方式增持公(gong)司(si)股(gu)(gu)(gu)(gu)(gu)份(fen)約36萬股(gu)(gu)(gu)(gu)(gu)，直接持股(gu)(gu)(gu)(gu)(gu)比(bi)例從1.94%變(bian)為2.4%，梁莉通(tong)過認(ren)購公(gong)司(si)定向(xiang)發行股(gu)(gu)(gu)(gu)(gu)份(fen)方式增持公(gong)司(si)股(gu)(gu)(gu)(gu)(gu)份(fen)150萬股(gu)(gu)(gu)(gu)(gu)，直接持股(gu)(gu)(gu)(gu)(gu)比(bi)例從0%變(bian)為2.66%。因為公(gong)司(si)股(gu)(gu)(gu)(gu)(gu)本增加(jia)，豫辰(chen)(chen)投資持股(gu)(gu)(gu)(gu)(gu)數(shu)量未(wei)發生變(bian)動，使得路(lu)明及其妻(qi)子梁莉擁(yong)有權(quan)益(yi)比(bi)例被動從95.24%變(bian)為90.12%。

(記者 曾健輝)

免責聲明：本(ben)文內容與數據僅供參考，不構成投資建議(yi)，使用(yong)前(qian)請核實。據此操(cao)作，風險自(zi)擔(dan)。